Viking Therapeutics, Inc. (VKTX)

USD 38.28

(-18.03%)

Market Cap (In USD)

4.26 Billion

Revenue (In USD)

-

Net Income (In USD)

-85.89 Million

Avg. Volume

3.83 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
17.23-99.41
PE
-
EPS
-
Beta Value
0.994
ISIN
US92686J1060
CUSIP
92686J106
CIK
1607678
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Brian Lian Ph.D.
Employee Count
-
Website
https://www.vikingtherapeutics.com
Ipo Date
2015-04-28
Details
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.